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Abstract: Twelve propolis samples from different parts of Libya were investigated for their
phytochemical constituents. Ethanol extracts of the samples and some purified compounds
were tested against Trypanosoma brucei, Plasmodium falciparum and against two helminth species,
Trichinella spiralis and Caenorhabditis elegans, showing various degrees of activity. Fourteen compounds
were isolated from the propolis samples, including a novel compound Taxifolin-3-acetyl-4′-methyl
ether (4), a flavanonol derivative. The crude extracts showed moderate activity against T. spiralis and
C. elegans, while the purified compounds had low activity against P. falciparum. Anti-trypanosomal
activity (EC50 = 0.7 µg/mL) was exhibited by a fraction containing a cardol identified as bilobol
(10) and this fraction had no effect on Human Foreskin Fibroblasts (HFF), even at 2.0 mg/mL, thus
demonstrating excellent selectivity. A metabolomics study was used to explore the mechanism
of action of the fraction and it revealed significant disturbances in trypanosomal phospholipid
metabolism, especially the formation of choline phospholipids. We conclude that a potent and highly
selective new trypanocide may be present in the fraction.
Keywords: propolis; Trypanosoma brucei; anthelminthic activity; metabolomics; alkylresorcinol; bilobol
1. Introduction
Several studies have confirmed the activity of propolis and its components against
protozoan parasites, particularly kinetoplastids such as Trypanosoma brucei, Leishmania donovani
and Trypanosoma cruzi, which cause sleeping sickness, visceral leishmaniasis and Chagas disease
respectively [1–4]. Recent studies have also observed antiprotozoal effects of propolis extracts against
Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax and Plasmodium ovale, the parasite
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species that cause malaria [5,6]. Samples of propolis have also been found to be effective
against Entamoeba histolytica and Guardia lamblia, which cause intestinal infections [7,8], and against
multicellular organisms such as intestinal worms including, cestodes (tapeworms), nematodes
(roundworms) and trematodes (e.g., Schistosoma spp.) [9,10]. In the present study we have carried out
further characterization and tests on Libyan propolis. Results of previous studies on Libyan propolis
are summarized in Table 1 and included reports of biological activities varying from antioxidant to
hypolipidaemic and hepatoprotective. We have previously reported the isolation of four compounds
isolated from Libyan propolis and performed preliminary tests for their anti-trypanosomal and
anti-leishmanial activity [4,6]. The current manuscript reports a much more detailed characterization
of the propolis extracts and identifies 14 additional purified compounds from the Libyan propolis,
several of which have not been reported before in the literature. These were tested for activity
against the helminths Trichinella spiralis and Caenorhabditis elegans, against P. falciparum and against
drug-sensitive and resistant strains of Trypanosoma brucei.
Table 1. Summary of previous studies on Libyan propolis.
Propolis Origin (Number of Samples) Extract Investigated Analysis Conducted Biological Activity Observed
Surman City, West Libya, (One sample) Ethanol extract/CAPE TLC investigation Cytotoxicity and Antioxidant activity [11]
Zawia City, West-Libya, (One sample) Ethanol extract Partial purification Inhibitory effect against S. aureus [12]








High activity against T. brucei,
L. donovani [4]
Surman City, West Libya, (One sample) Aqueous extract None In vivo hypolipidaemic and antiatherogeniceffects in mice [13]
Surman City, West Libya (One sample) Aqueous extract None Hepatoprotective and hypolipidemic effectsin guinea pigs [14]
Different Geographic areas West, East,
South East and South West of Libya
(12 samples)
Ethanol extract LC-MS, PCA, analysiscombined with HCA
Activity against T. brucei, L. donovani, P.
falciparum, C. fasciculata and M. marinum [6]
CAPE = Caffeic acid phenethyl ester.
2. Results
2.1. Anti-Helminthic Activity of the Propolis Samples
Crude extracts of the propolis samples were tested against helminths (Table 2). Samples
P1–P5 showed promising activity against T. spiralis but samples P6–P12 all gave <20% inhibition.
This anthelminthic activity appeared to be species-specific as none of the samples displayed only weak
inhibition of C. elegans (<20%) at 1 µg/mL and 10 µg/mL.
Table 2. Anthelminthic activity of crude propolis extracts P1–P5 against T. spiralis (n = 3).
Propolis Samples Inhibition of T. spiralis 1 µg/mL 10 µg/mL
P1 19.5 ± 3.5 63.1 ± 0.5
P2 38.9 ± 0.1 57.2 ± 6.4
P3 51.9 ± 0.1 63.6 ± 0.3
P4 59.3 ± 0.1 61.3 ± 0.7
P5 4.77 ± 0.21 56.2 ± 5.2
Nitazoxanide a 28.7 ± 11.8
Levamisole b 56.7 ± 3.9
a 3.13 µg/mL; b 2.1 µg/mL.
2.2. Isolation and Characterization of Compounds from Samples P1, P2, P7 and P9
The isolation and characterization of three diterpenes and a lignan from sample P1 was reported
in our previous paper [4]. In the current study 14 additional compounds (Table 3) were isolated and
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characterized by comparison of their 1H- and 13C-NMR spectra to literature data (Tables S1–S14); their
structures are given in Figure 1.





Formula m/z -Ve Ion Class of Compound
(1) 17.7 13-Epitorulosolol P1 C20H34O2 305.4812 Diterpene
(2) 22.7 Demethylpiperitol P2 C19H18O6 341.1211 Lignan
(3) 20.3 5′-Methoxypiperitol P2 C21H22O7 385.1136 Lignan
(4) 17.7 Taxifolin-3-acetyl-4′methyl ether P1 C18H16O8 359.0766 Flavanone
(5) 25.7 Cycloartanol P7 C30H50O 425.3821 Cycloartane triterpene
(6) 29.2 Mangiferolic acid P7 C30H48O3 455.7123 Cycloartane triterpene
(7) 21.7 Mangiferonic acid P7 C30H46O3 453.6934 Cycloartane triterpene
(8) 41.8 Ambolic acid C31H51O3 P7 C31H50O3 469.729 Cycloartane triterpene
(9) 33.8 27-Hydroxymangiferonic acid P7 C30H46O4 469.6982 Cycloartane triterpene
(10) 37.8 Cardol plus mangiferolic acid (6) P7 C21H34O2 317.2489, 455.7123 Resorcinol, Cycloartane
(11) 27.1 Acetylisocupressic acid P9 C20H32O3 319.1711 Diterpene
(12) 25.4 Agathadiol P9 C20H34O2 305.4838 Diterpene
(13) 22.3 Isocupressic acid P9 C20H32O3 319.4791 Diterpene
(14) 22.2 Isoagatholal P9 C20H32O2 303.2412 Diterpene
Figure 1. Structures of the compounds isolated from Libyan propolis in this study.
2.3. Characterization of Compound 4 as 3-Acetoxy-5,7,3′-trihydroxy-4′-methoxyflavanone or
Taxifolin-3-acetyl-4′-methyl ether
The NMR data and the optical rotation value [α] = +1.6 for this compound suggest the same
configuration as reported for (2R,3R)-taxifolin-3-acetate isolated from Chrysothamnus viscidiflorus ssp.
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viscidiflorus by Stevens et al. [15]. These authors also isolated a methyl ether that was identified as
taxifolin-3-acetate-x′-methyl ether since they could not establish the position of the methoxy moiety at
-C-3′ or C-4′. In the current study the structure of compound 4 (Figure 1) was determined by NMR,
COSY and mass spectrometry (Figures S1–S5). 1H-NMR data for 4 showed a highly deshielded and
H-bonded proton at δ 11.52 (s), a methoxy at δ 3.85 and an acetoxy at δ 1.96. It also showed two
coupled protons on oxygen-bearing carbons at δ 5.20 (d, J = 11.7 Hz) and δ 5.75 (d, J = 11.7 Hz), four
sets of aromatic protons made up of two meta-split protons at δ 6.10 and 6.05, typical of the A-ring
protons of a flavonoid, and two multiplets, at δ 6.93 (1H, m) and δ 6.86 (2H, m) (Table S1). The HSQC
spectrum (Figure S4), shows the attachment of the carbon-bonded protons to their respective carbons.
The HMBC spectrum (Figure S5), revealed that the de-shielded phenolic proton (δH 11.52) coupled to
three aromatic carbons, 97.4 (C-6), 101.8 (C-10) and 164.4 (C-5). The protons at δ 6.10 (1H, d, J =2.4 Hz)
(H-6) and 6.05 (H-8) (1H, d, J = 2.3 Hz) showed 3J correlations to C-10 and to each other’s carbons and
weak correlations 2J to a carbon at 164.4 ppm (C-7) while H-8 had a weak correlation to 163.1 ppm (C-9).
The proton doublet at δ 5.75(1H, d, J = 11.7 Hz) (attached to C-3 at 72.2 ppm) was coupled (COSY)
to another proton doublet at δ 5.20 (attached to C-2 at 81.5 ppm), and they had HMBC correlations
to a carbonyl at 169.2 ppm which also had coupling from the methyl at 1.96 ppm, indicative of the
3-acetoxy moiety. The proton at δ 5.20 coupled to C-3 and C-4 (191.7 ppm) and to 109.3, 121.9, and
127.0 ppm, C-6′, C-2′ and C-1′, respectively. The protons attached to carbons C-6’ and C-2’ at δ 6.93 and
δ 6.86 coupled with the carbon at 81.5 ppm (C-2) and to each other’s carbon (109.3 and 121.9 ppm) and
146.7 ppm (C-4’) which also had coupling from the 4’-OCH3 at δ 3.85 ppm. All assignments were made
as given in Table S1. Also evident in the spectrum is a fatty contamination with signals between δ 0.50
and 2.60 ppm. This was a mixture of common fatty acids that are not known to have any antimicrobial
activity; we were unable to further purify 4 from this fatty residue as all such attempts resulted in the
loss of the compound together with the contaminants.
2.4. Testing of the Antiparasite Activity of the Isolated Compounds
Ten of the isolated compounds were tested against pentamidine-resistant and -sensitive strains of
T. brucei. The results for the activity against T. brucei (s427) and pentamidine resistant strain T. brucei B48
showed that the isolated compounds exhibited significant activity against Trypanosoma spp., with the
lowest EC50, 0.70 µg/mL, being observed for cardol 10 (Table 4). B48 cells were equally sensitive to all
the propolis-derived compounds, but displayed >1000-fold resistance to pentamidine and were also
resistant to melaminophenyl arsenical drugs [16].
Table 4. EC50 values (µg/mL) of the antiprotozoal activities of compounds isolated from Libyan
propolis tested against T. brucei and P. falciparum.
Compound T. brucei (s427) a T. brucei (B48) a P. falciparum a
(2) 2.7 ± 0.2 2.68 ± 0.04 17.5 ± 0.1
(3) 13.1 ± 0.1 12.4 ± 1.6 -
(5) 3.7 ± 0.1 3.42 ± 0.08 *
(6) - - *
(7) 14.6 ± 0.2 14.7 ± 0.4 49.2 ± 9.5
(8) - - *
(9) 35.2 ± 0.6 34.9 ± 0.3 *
(10) 0.70 ± 0.03 0.70 ± 0.06 12.4 ± 2.1
(11) 25.0 ± 0.2 25.6 ± 0.9 -
(12) 7.0 ± 0.6 6.90 ± 0.45 -
(13) 3.0 ± 0.1 2.73 ± 0.11 *
(14) 10.4 ± 0.1 10.2 ± 0.8
Pentamidine 1 0.00012 ± 0.00003 0.255 ± 0.009 -
Chloroquine 1 - - 0.0034 ± 0.00003
* Not active at 0.1 mg/ml. a Average of EC50 (µg/mL) ± Standard error of mean (n = 3) for the isolated compounds;
- not tested. 1 for the control compounds pentamidine and chloroquine the EC50 was expressed as µM.
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Some of the isolated compounds were tested also against P. falciparum. The highest activity
was again obtained for the cardol fraction. The activity of the isolated compounds was much lower
against P. falciparum than against T. brucei. The anthelminthic activity of some of the compounds
isolated from propolis was tested against T. spiralis. The results indicate that only compounds 13
and 14 had low levels of anti-helminthic activity (31.8 ± 3.4 and 36.1 ± 5.6% inhibition, respectively,
at 1 µg/mL). Compounds 1 and 4–8 had no activity against T. spiralis, nor did the two labdane
diterpenes, 13-epirutosolal and 13-epicupressic acid, isolated from P1 in our previous study [4].
2.5. Metabolomic Profiling of the Effect of the Cardol-Rich Fraction 10 against T. brucei
Metabolomics testing of the cardol-rich fraction was carried out with trypanosomes with the
assumption this would reveal cardol-specific effects as the mangiferonic acid contaminant had low
activity on its own. Three control samples were compared with four samples treated with the cardol
fraction; the positive ion mode data is shown in Table S15. With this number of samples, it is difficult to
be certain that data are normally distributed and that p-values are valid. However, one might hope to
see changes of several metabolites within the same class or biochemical pathway, highlighting a clear
theme in the metabolite changes. Indeed, we found that many long chain lipids are depleted, and there
are changes in several phosphocholine and phosphoserine lipids containing highly unsaturated fatty
acids with chain lengths ≥ C20. Corresponding elevations in choline and CDP-choline suggest that the
cells might be countering the effects of the treatment by increasing these intermediates. The negative
ion data shown in Table S16 revealed that the abundance of several phosphatidyl glycerol (PG) and
phosphatidyl inositol (PI) lipids was lowered by the treatment. Thus, the treatment seems to be
depleting the cells of a wide range of lipids. Comparison of the growth medium for treated versus
control indicates that many of the lipids which are reduced in the cell extracts were greatly elevated
in the growth medium. This is more marked for the negative ion data where there are many PI and
PG lipids which are at much higher levels in the medium from the treated trypanosomes (Table S17).
However, there are also some of lipids observed in positive mode in the cells that are lowered and that
are correspondingly elevated in the growth medium (Table S18). In addition, there are a number of
fatty acids that are elevated to some extent in the growth medium of the treated versus the control
cells (Table S17). The presence of lipids in the growth medium may be due to cell lysis though the
viability of the cells post-treatment did not indicate extensive cell death. There were traces of high
energy phosphates (GTP, GDP, ATP, Figure 2, Table S17) in the growth medium of the treated cells and
again this could be due to cell lysis. However, the trypanosomes contain oxidised trypanothione as
typical intra-cellular product and there is no evidence of this being released into the growth medium.
Figure 2. Extracted ion traces showing leakage of small amounts of high energy phosphates GTP, ATP
and GDP into the growth medium in the treated cells.
3. Discussion
One of the most consistent of the many biological activities of propolis, regardless of its quite
different compositions and origins, is its antiprotozoal activity. Clearly, bees target plants that can
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afford them this type of biological protection. Anthelminthic testing of propolis has been much less
extensively studied, although there are some previous studies that have observed this activity [10].
In this study the in vitro anthelminthic activity of Libyan propolis against T. spiralis and C. elegans
was assessed. Samples P1–P4, at a concentration of 10 µg/mL, exhibited 61–80% inhibition against
T. spiralis. We previously reported that these propolis samples have low toxicity against mammalian
cells [6] and they might thus have utility to purge T. spiralis from the intestine. The crude extracts
of P6-P12 were not active against T. spiralis but compounds 13 and 14 isolated from sample P9 had
some weak and variable activity against T. spiralis and the results suggest that propolis affords less
protection against helminths than against protozoa, which are the more dangerous pathogens for bees.
Samples P1 and P2 had a composition typical of Mediterranean propolis [17], which has been
reported to exhibit biological properties such as antioxidant, anti-proliferative, anti-inflammatory and
had neuroprotective effects. The botanical origin of such propolis samples has yet to be identified,
but the diterpenic profile suggests that the source plant should be in the Cupressaceae family, which
is common in the region. Diterpenes such as 13-epitorulosol (1) and 13-epicupressic acid were also
isolated from the leaves of Cupressaceae family member Cryptomeria japonica [18].
MPLC fractionation of P7, from the tropical region of Southeast Libya, was carried out and
this resulted in the isolation of a number cycloartane triterpenes: cycloartanol (5), mangiferolic
acid (6), mangiferonic acid (7), ambolic acid (8) and 27-hydroxymangeferonic acid (9); these were
previously isolated from Cameroonian propolis [19]. Most of the compounds isolated from it displayed
significant anti-protozoal activity, especially 5. Many studies on propolis from different African
regions such as Kenya, Cameroon, Congo and Ethiopia, showed that triterpenoids are major chemical
components [20,21]. Three more cycloartane-type triterpenes were isolated and identified from East
Java propolis, and Macaranga tanarius L. parasol tree and Mangifera indica L. (mango) were named as
the plant sources [22]. In addition, a fraction containing about 60% cardol (10) was isolated from P7.
This compound was isolated previously from hydrogenated cashew nut shell [23] and from Brazilian
propolis [24]. Of all the isolated compounds tested, this compound has the highest anti-trypanosomal
activity, despite the fact that the crude propolis sample had relatively low activity. Importantly,
the compounds isolated from the propolis samples reported in this work had no measurable effects on
the HFF human cell line at up to 2 mg/mL, demonstrating excellent selectivity.
Metabolomic profiling of the effects of the cardol rich fraction suggested that it might be
targeting the cell membrane and acting rather like a surfactant, extracting lipid from the membrane,
making it leaky. Thus, its mode of action might be similar to that of Miltefosine an established
anti-leishmanial drug that changes microbial membrane fluidity [25]. Alkyl resorcinols have been
found to promote leakage of electrolytes from erythrocytes [26] and this is consistent with the leakage
of high energy phosphates observed in the current data. Alkyl resorcinols have been found to be
potent inhibitors of phospholipase Cγ1 which is responsible for hydrolysis of phosphoinositol lipids
releasing diacylglycerol and phosphoinositol [27], but the current data do not indicate such an effect
in T. brucei since the treatment lowered several PI lipids. Alkyl resorcinols have been found to have
antibacterial, antifungal and anti-helminthic activity while having low toxicity towards mammals [26].
In conclusion, Libyan Propolis shows activity against a range of parasites. Its production is
commercially viable and it is non-destructive since bees collect it without damaging the plants they
collect from. The main problem of exploiting the biological activity of a natural product such as propolis
is to guarantee a standardized supply of material. In addition, some of the active compounds isolated
from propolis could be used as lead compounds for producing more potent drugs. The exact purpose
and usage of this intriguing material still have to be fully elucidated. One thing is clear propolis is
always biologically active and can potentially be harvested in large amounts in an environmentally
friendly way. Moreover, the most active compound, cardol, also known as bilobol, is easily synthesized
and derivatized, and thus open to optimization [28].
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4. Materials and Methods
4.1. Reagents and Materials
Absolute ethanol, HPLC grade acetonitrile, hexane, methanol, formic acid and syringe filters
(Acrodisc®) were obtained from Fisher Scientific (Loughborough, UK). Chloroform, dimethyl sulfoxide
(DMSO), deuterated chloroform, DMSO-d6, silica gel 60 (0.04–0.06 mm mesh size) and Wilmad NMR
tubes were obtained from Sigma-Aldrich (Gillingham, Dorset, UK). HPLC grade water was produced
in-house using a Milli Q system. Twelve propolis samples were collected from different localities
in Libya. Six silica gel cartridges (24 g) for the Revelris MPLC system were obtained from Alltech
Ltd. (Carnforth, Lancs, UK). The origin of the propolis samples was described in detail in a previous
paper [6].
4.2. Extraction of Propolis Samples
Using sonication at 50 ◦C for 1 h, 20 g of each propolis sample (P1–P12) was extracted thrice
with 100 mL ethanol. The extracts were filtered and combined after removal of solvents with a rotary
evaporator. The solvent-free extracts were re-dissolved in 5 mL ethyl acetate and stored for further use.
4.3. Column Chromatography
Crude P1 extract (2.0 g) was fractionated on silica gel (50 g) using varying proportions of
hexane/ethyl acetate in a stepwise gradient. Fractions of 50 mL were collected and the second
fraction P1-2 (252 mg) and third fraction P1-3, (111 mg), both eluted with hexane/ethyl acetate
(90:10), were selected for further purification using medium-pressure liquid chromatography (MPLC).
The ethanolic extract of P2 was similarly fractionated and fraction P2-12 (354 mg, eluted with
hexane/ethyl acetate (60:40)) and fraction P2–24 (204 mg; hexane/ethyl acetate (30:70)) were also
selected for further purification.
4.4. Purification of Column Fractions Using MPLC
Separation by MPLC was carried out on a Grace Reveleris system (Alltech Ltd.) fitted with
commercially packed silica or C18 silica cartridges (Alltech Ltd.). P1-3 (1 g) was dissolved in hexane:
EtOAc (50:50), absorbed on 2 g of Celite, and introduced into a dry loader for the MPLC. A 24.0 g silica
column and 12 mL/min flow rate was used; program: 100% hexane to hexane: ethyl acetate (80:20) in
30 min, then to 100% ethyl acetate at 50 min, yielding 17.7 mg of 13-epitorulosol (1) from P1. Column
fraction P1-2 was loaded onto the MPLC system with a 12 g silica gel cartridge and eluted with a
stepwise gradient of ethyl acetate in hexane, yielding 17.8 mg of taxifolin-3-acetate-4′-methylether (4).
The same procedure yielded 22.7 mg of demethylpiperitol (2) from 354 mg of P2-12 (354 mg). Fraction
P2-24 (208 mg) was eluted from a Grace 12 g C-18 cartridge with acetonitrile: water (40:60, 12 mL/min,
30 min; linear increase to 100% acetonitrile over 30 min), yielding 20.3 mg of 5′-methoxypiperitol (3).
Fractionation of the ethanol extract of sample P7 (1 g) on the MPLC system fitted with a 24 g silica
gel cartridge (100% hexane to 100% ethyl acetate over 60 min; flow rate of 24 mL/min), yielded six
compounds: 25.7 mg of cycloartanol (5), 37.8 mg of a fraction containing cardol (10) and mangiferolic
acid (6), 29.2 mg of mangiferolic acid (6), 21.7 mg of mangiferonic acid (7), 41.8 mg of ambolic acid (8),
33.8 mg of 27-hydroxymangiferonic acid (9). Fractionation of the ethanol extract of P9 (1 g) yielded four
compounds. 27.1 mg acetylisocupressic acid (11), 25.4 mg of agathadiol (12), 22.3 mg of isocupressic
acid (13) and 22.2 mg of isoagatholal (14).
4.5. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) and HPLC with
UV/Evaporative Light Scattering Detection (ELSD)
Profiling of the ethanolic extract of propolis (EEP) and selected sub-fractions from MPLC was
carried out using an Agilent 1100 HPLC system (Agilent Technologies LDA UK Ltd, Stockport,
Cheshire, UK) linked to a Shodex ELSD (SEDEX75, SEDERE, Olivet, France) and an Agilent UV detector
Molecules 2019, 24, 1041 8 of 11
set at 290 nm. The sample extracts were dissolved in water-acetonitrile (70:30) at a concentration of
0.5 mg/mL. An ACE-C18 column (150 × 3 mm, 3 µm) (HiChrom, Reading, UK) was employed for
separation with mobile phases A (water) and B (ACN) at a flow rate of 300 µL/min. The gradient
elution was 0–15 min gradient, 30–50% B; 15–25 min, 50% B; 25–40 min gradient, 50–70% B; 40–50 min,
70% B; 50–51 min increasing to 100% B; 51–59 min 100% B; 60–70 min back to 30% B. Propolis fractions
obtained from column chromatography and MPLC were dissolved in methanol (1 mg/mL) and 10 µL
of the solutions were subjected to LC-MS (LTQ Orbitrap (Thermo Fisher, Perth, Scotland, UK) in
negative ion mode with a needle voltage of −4.0 kV, and sheath and auxiliary gas flows of 50 and
10 arbitrary units, respectively. Separation was carried out using an ACE-C18 column (150 × 3 mm,
3 µm); mobile phase: 0.1% v/v formic acid in water (A) and 0.1% v/v formic acid in ACN (B), flow rate
300 µL/min. The same gradient program as above was used.
4.6. Nuclear Magnetic Resonance (NMR) Spectroscopy
Samples were dissolved in DMSO-d6 or CDCl3 and 1H-, 13C- and 2D-NMR spectra (COSY, HMBC,
HSQC) were acquired on an AV600 or AV400 FTNMR spectrophotometer (Bruker, Coventry, UK).
4.7. Software and Data Processing for LC-HR-MS
Xcalibur 2.2 from Thermo Fisher Scientific was used to check the raw LC-HRMS and GC-MS data
and generate the MS-based chromatograms shown in the manuscript. Clarity from DataApex (Prague,
Czech Republic) was used to handle the LC-UV-ELSD data.
4.8. In Vitro Testing against T. brucei and P. falciparum and Cytotoxicity
Cytotoxicity [29] and testing against T. brucei and P. falciparum [6] was carried out as
described previously.
4.9. In Vitro Anti-Helminthic Activity of P1–P12 Against Trichinella spiralis
Female and male C57BL/6 mice aged 8–12 weeks and 20–25 g in weight, were kept under
conventional animal house conditions in accordance with the Home Office regulations in the animal
unit at the University of Strathclyde and the terms of the Home Office license (Number P894DB549).
Experimental groups consisted of a minimum of five mice. Infective muscle larvae were obtained
from digestion of infected mice (>30 days post infection). Mice were killed by CO2 inhalation and
skins, snouts, extremities and abdominal organs were removed. The carcasses were cut into pieces
and homogenized in a Kenwood blender. The material was digested in 200 ml 0.9% NaCl/0.5%
Pepsin/0.5% HCl solution/mouse at 37 ◦C under agitation for 1.5 h, and filtered through a coarse sieve
(mesh 1 mm) to remove undigested tissue and bone. The larvae were collected by a series of three
successive washings and sedimentations in 0.9% NaCl, suspended in 50 mL 0.9% NaCl, and counted
using a Leica light microscope. Experimental mice were infected orally with 400 larvae in 200 µL 0.1%
agarose culture medium.
The resazurin assay was performed in 96-well culture plates. T. spiralis was prepared as described
above. 1% v/v of 10,000 units/mL penicillin and 10 mg/mL streptomycin (Sigma-Aldrich, Poole,
UK) were added to eliminate any bacterial contamination. Prior to the experiment, propolis samples
were diluted to 1 and 10 µg/mL in culture medium. 100 µL of worms and 100 µL of propolis
samples, medium or known anthelminthic (nitazoxanide (3.13 µg/mL) or levamisole (2.1 µg/mL);
both Sigma-Aldrich) were added to each well of a 96-well culture plate. Resazurin (Cambridge
Bioscience, Cambridge, UK; 125 mg/L) was added aseptically at 10% v/v culture medium at various
time points. The plate was incubated at 37 ◦C in 5% CO2 at various time points. Resazurin reduction
was monitored spectrophotometrically at 570 nm and 600 nm over a period of time with absorbance
taken at specific time intervals over the period, blanking with medium only. Resazurin reduction by
viable parasites was expressed as % reduction as a function of incubation time, and quantified by
fluorescence at λex = 544 nm; λem = 590–610 nm (Polarstar, BMG Labtech, Aylesbury, UK). The effect of
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drug treatment on parasite survival was determined as the mean suppression of fluorescence compared
to control values.
4.10. Metabolomics Experiments
T. brucei bloodstream forms of strain T. brucei 427 were grown in 75 cm2 flasks with HMI-9
medium, supplemented with fetal calf serum (FCS, 10%, v/v), incubated at 37 ◦C and 5% CO2 for
two days until mid-log phase. Cultures were then treated with 0.5 × EC50 of the test samples and
incubated for 10 h (37 ◦C, 5% CO2). Parasite viability was verified at the end of the incubation
and was not significantly different between control and treated cultures. From each culture 1 × 108
cells/sample were transferred to a 50 mL falcon tube and quenched by rapidly cooling cells to 4 ◦C
on dry ice/ethanol before centrifugation (1250× g, 4 ◦C, 10 min). The cells were re-suspended in
1 mL of phosphate buffered saline (PBS) at 4 ◦C, transferred to an Eppendorf tube, pelleted (1250× g,
4 ◦C, 10 min), washed twice in 1 mL of PBS at 4 ◦C and finally resuspended in 200 µL of chloroform:
methanol: water (1:3:1 (CMW)) at 4 ◦C, mixing well. These samples were left on a see-saw rocking
shaker in the cold room (4 ◦C) for 1 h at maximum speed. In addition, 10 µL of the spent medium
from each treatment was mixed with 200 µL CMW and centrifuged (13,000 rpm, 10 min, 4 ◦C); 180 µL
of the supernatant was flushed with argon before storage at −80 ◦C. LC-MS analysis was carried out
using a ZIC-pHILIC column (150 × 4.6 mm, 5 µm) connected to a mass spectrometer as described
previously [30]. The data was extracted by using m/z Mine 2.14 [31]. Most metabolites were identified
to MSI level 2 (exact mass matching to <3 ppm) with some being annotated at MSI level 1 where
retention time was matched to that of an authentic standard.
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